Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Driss Chaoui

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Ejhaem|February 26, 2024
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN studyKamel Laribi, Xavier Leleu, Nathalie Texier, et al.
Haematologica|November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic AnemiaEtienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Haematologica|August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY studyThomas Chalopin, Cyrille Hulin, Bruno Royer, et al.
Cancer Medicine|March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Blood|March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialPhilippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
Blood|May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Ejhaem|February 26, 2024
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN studyKamel Laribi, Xavier Leleu, Nathalie Texier, et al.
Haematologica|November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic AnemiaEtienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Haematologica|August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY studyThomas Chalopin, Cyrille Hulin, Bruno Royer, et al.
Cancer Medicine|March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Blood|March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialPhilippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
Blood|May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Pageof 3